Trade IQVIA Holdings Inc. - IQV CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
| Spread | 0.31 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
IQVIA Holdings Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 227 |
| Open* | 222.57 |
| 1-Year Change* | 9.82% |
| Day's Range* | 222.57 - 230.09 |
| 52 wk Range | 167.42-241.86 |
| Average Volume (10 days) | 1.01M |
| Average Volume (3 months) | 25.53M |
| Market Cap | 38.91B |
| P/E Ratio | 35.77 |
| Shares Outstanding | 182.50M |
| Revenue | 14.86B |
| EPS | 5.96 |
| Dividend (Yield %) | N/A |
| Beta | 1.49 |
| Next Earnings Date | Feb 8, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 17, 2024 | 227.00 | -1.20 | -0.53% | 228.20 | 230.55 | 226.86 |
| Apr 16, 2024 | 228.99 | -3.01 | -1.30% | 232.00 | 232.00 | 227.71 |
| Apr 15, 2024 | 230.89 | -4.08 | -1.74% | 234.97 | 236.39 | 229.87 |
| Apr 12, 2024 | 233.98 | -0.92 | -0.39% | 234.90 | 236.48 | 232.70 |
| Apr 11, 2024 | 237.79 | -0.80 | -0.34% | 238.59 | 239.30 | 236.64 |
| Apr 10, 2024 | 239.14 | 0.82 | 0.34% | 238.32 | 240.35 | 235.60 |
| Apr 9, 2024 | 245.27 | 2.53 | 1.04% | 242.74 | 246.49 | 242.74 |
| Apr 8, 2024 | 241.36 | 1.97 | 0.82% | 239.39 | 242.70 | 238.81 |
| Apr 5, 2024 | 241.38 | 2.95 | 1.24% | 238.43 | 241.90 | 237.42 |
| Apr 4, 2024 | 238.21 | -5.49 | -2.25% | 243.70 | 244.79 | 238.18 |
| Apr 3, 2024 | 242.78 | -1.12 | -0.46% | 243.90 | 245.51 | 241.58 |
| Apr 2, 2024 | 245.34 | -0.83 | -0.34% | 246.17 | 246.61 | 242.17 |
| Apr 1, 2024 | 248.52 | -4.27 | -1.69% | 252.79 | 252.84 | 247.08 |
| Mar 28, 2024 | 252.43 | 0.53 | 0.21% | 251.90 | 253.60 | 246.60 |
| Mar 27, 2024 | 252.41 | 3.38 | 1.36% | 249.03 | 252.49 | 248.71 |
| Mar 26, 2024 | 247.68 | -0.52 | -0.21% | 248.20 | 249.68 | 247.04 |
| Mar 25, 2024 | 248.58 | -2.47 | -0.98% | 251.05 | 253.49 | 247.95 |
| Mar 22, 2024 | 252.27 | -0.69 | -0.27% | 252.96 | 254.34 | 251.03 |
| Mar 21, 2024 | 254.19 | 2.08 | 0.83% | 252.11 | 256.03 | 251.93 |
| Mar 20, 2024 | 252.67 | -0.18 | -0.07% | 252.85 | 254.13 | 250.54 |
IQVIA Holdings Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Thursday, April 25, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q1 2024 IQVIA Holdings Inc Earnings Release Q1 2024 IQVIA Holdings Inc Earnings ReleaseForecast -Previous - |
| Tuesday, July 30, 2024 | ||
| Time (UTC) 12:30 | Country US
| Event Q2 2024 IQVIA Holdings Inc Earnings Release Q2 2024 IQVIA Holdings Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 14410 | 13874 | 11359 | 11088 | 10412 |
| Revenue | 14410 | 13874 | 11359 | 11088 | 10412 |
| Cost of Revenue, Total | 9382 | 9233 | 7500 | 7300 | 6746 |
| Gross Profit | 5028 | 4641 | 3859 | 3788 | 3666 |
| Total Operating Expense | 12611 | 12507 | 10641 | 10335 | 9673 |
| Selling/General/Admin. Expenses, Total | 2071 | 1964 | 1789 | 1734 | 1716 |
| Depreciation / Amortization | 1130 | 1264 | 1287 | 1202 | 1141 |
| Unusual Expense (Income) | 28 | 46 | 65 | 99 | 70 |
| Operating Income | 1799 | 1367 | 718 | 753 | 739 |
| Interest Income (Expense), Net Non-Operating | -403 | -369 | -410 | -438 | -406 |
| Other, Net | -33 | 130 | 65 | 37 | -5 |
| Net Income Before Taxes | 1363 | 1128 | 373 | 352 | 328 |
| Net Income After Taxes | 1103 | 965 | 301 | 236 | 234 |
| Minority Interest | 0 | -5 | -29 | -36 | -25 |
| Equity In Affiliates | -12 | 6 | 7 | -9 | 15 |
| Net Income Before Extra. Items | 1091 | 966 | 279 | 191 | 224 |
| Net Income | 1091 | 966 | 279 | 191 | 259 |
| Income Available to Common Excl. Extra. Items | 1091 | 966 | 279 | 191 | 224 |
| Income Available to Common Incl. Extra. Items | 1091 | 966 | 279 | 191 | 259 |
| Diluted Net Income | 1091 | 966 | 279 | 191 | 259 |
| Diluted Weighted Average Shares | 190.6 | 195 | 195 | 199.6 | 208.2 |
| Diluted EPS Excluding Extraordinary Items | 5.72403 | 4.95385 | 1.43077 | 0.95691 | 1.07589 |
| Diluted Normalized EPS | 5.84291 | 5.15566 | 1.69976 | 1.28945 | 1.31575 |
| Total Extraordinary Items | 0 | 35 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 3728 | 3652 | 3739 | 3562 | 3541 |
| Revenue | 3728 | 3652 | 3739 | 3562 | 3541 |
| Cost of Revenue, Total | 2443 | 2398 | 2407 | 2321 | 2331 |
| Gross Profit | 1285 | 1254 | 1332 | 1241 | 1210 |
| Total Operating Expense | 3204 | 3181 | 3360 | 3090 | 3088 |
| Selling/General/Admin. Expenses, Total | 482 | 513 | 583 | 517 | 483 |
| Depreciation / Amortization | 259 | 253 | 357 | 248 | 270 |
| Unusual Expense (Income) | 20 | 17 | 13 | 4 | 4 |
| Operating Income | 524 | 471 | 379 | 472 | 453 |
| Interest Income (Expense), Net Non-Operating | -165 | -135 | -122 | -104 | -92 |
| Other, Net | 16 | 26 | 18 | -8 | -33 |
| Net Income Before Taxes | 375 | 362 | 275 | 360 | 328 |
| Net Income After Taxes | 294 | 291 | 227 | 290 | 257 |
| Minority Interest | 0 | 0 | 0 | ||
| Equity In Affiliates | 3 | -2 | 0 | -7 | -1 |
| Net Income Before Extra. Items | 297 | 289 | 227 | 283 | 256 |
| Net Income | 297 | 289 | 227 | 283 | 256 |
| Income Available to Common Excl. Extra. Items | 297 | 289 | 227 | 283 | 256 |
| Income Available to Common Incl. Extra. Items | 297 | 289 | 227 | 283 | 256 |
| Diluted Net Income | 297 | 289 | 227 | 283 | 256 |
| Diluted Weighted Average Shares | 186.7 | 188.6 | 188.5 | 189.4 | 191.1 |
| Diluted EPS Excluding Extraordinary Items | 1.59079 | 1.53234 | 1.20424 | 1.49419 | 1.33961 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | 1.67477 | 1.6048 | 1.26117 | 1.5112 | 1.35601 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 4981 | 4763 | 5090 | 4126 | 3874 |
| Cash and Short Term Investments | 1309 | 1477 | 1902 | 899 | 938 |
| Cash & Equivalents | 1216 | 1366 | 1814 | 837 | 891 |
| Short Term Investments | 93 | 111 | 88 | 62 | 47 |
| Total Receivables, Net | 2960 | 2609 | 2466 | 2638 | 2463 |
| Accounts Receivable - Trade, Net | 2917 | 2551 | 2410 | 2582 | 2394 |
| Prepaid Expenses | 151 | 156 | 159 | 138 | 151 |
| Other Current Assets, Total | 561 | 521 | 563 | 451 | 322 |
| Total Assets | 25337 | 24689 | 24564 | 23251 | 22549 |
| Property/Plant/Equipment, Total - Net | 863 | 903 | 953 | 954 | 434 |
| Property/Plant/Equipment, Total - Gross | 1703 | 1668 | 1626 | 1551 | 1001 |
| Accumulated Depreciation, Total | -840 | -765 | -673 | -597 | -567 |
| Goodwill, Net | 13921 | 13301 | 12654 | 12159 | 11800 |
| Intangibles, Net | 4820 | 4943 | 5205 | 5514 | 5951 |
| Long Term Investments | 162 | 164 | 162 | 152 | 142 |
| Other Long Term Assets, Total | 590 | 615 | 500 | 346 | 348 |
| Total Current Liabilities | 5578 | 5241 | 4558 | 3945 | 3534 |
| Accounts Payable | 437 | ||||
| Accrued Expenses | 2414 | 2189 | 2116 | 1855 | 1638 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 157 | 100 | 149 | 100 | 100 |
| Other Current Liabilities, Total | 2362 | 2331 | 1712 | 1415 | 1359 |
| Total Liabilities | 19572 | 18647 | 18563 | 17248 | 15835 |
| Total Long Term Debt | 12819 | 12211 | 12506 | 11545 | 10907 |
| Long Term Debt | 12595 | 12034 | 12384 | 11545 | 10907 |
| Deferred Income Tax | 464 | 410 | 338 | 646 | 736 |
| Minority Interest | 0 | 279 | 260 | 240 | |
| Other Liabilities, Total | 711 | 785 | 882 | 852 | 418 |
| Total Equity | 5765 | 6042 | 6001 | 6003 | 6714 |
| Common Stock | 3 | 3 | 3 | 3 | 3 |
| Retained Earnings (Accumulated Deficit) | 3334 | 2243 | 1277 | 998 | 807 |
| Treasury Stock - Common | -7740 | -6572 | -6166 | -5733 | -4770 |
| Unrealized Gain (Loss) | |||||
| Other Equity, Total | -727 | -406 | -205 | -311 | -224 |
| Total Liabilities & Shareholders’ Equity | 25337 | 24689 | 24564 | 23251 | 22549 |
| Total Common Shares Outstanding | 185.7 | 190.6 | 191.2 | 192.3 | 197.5 |
| Additional Paid-In Capital | 10895 | 10774 | 11092 | 11046 | 10898 |
| Payable/Accrued | 645 | 621 | 581 | 575 | |
| Capital Lease Obligations | 224 | 177 | 122 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 5208 | 5329 | 5328 | 4981 | 4752 |
| Cash and Short Term Investments | 1332 | 1492 | 1598 | 1309 | 1361 |
| Cash & Equivalents | 1224 | 1382 | 1494 | 1216 | 1274 |
| Short Term Investments | 108 | 110 | 104 | 93 | 87 |
| Total Receivables, Net | 3276 | 3184 | 3105 | 2960 | 2687 |
| Accounts Receivable - Trade, Net | 3227 | 3139 | 3063 | 2917 | 2640 |
| Prepaid Expenses | 177 | 179 | 165 | 151 | 176 |
| Other Current Assets, Total | 423 | 474 | 460 | 561 | 528 |
| Total Assets | 25977 | 26036 | 25739 | 25337 | 24223 |
| Property/Plant/Equipment, Total - Net | 790 | 829 | 845 | 863 | 840 |
| Goodwill, Net | 14288 | 14178 | 14015 | 13921 | 13177 |
| Intangibles, Net | 4907 | 4942 | 4757 | 4820 | 4718 |
| Long Term Investments | 214 | 208 | 201 | 162 | 151 |
| Other Long Term Assets, Total | 570 | 550 | 593 | 590 | 585 |
| Total Current Liabilities | 6589 | 6543 | 6657 | 5578 | 5253 |
| Payable/Accrued | 3133 | 3007 | 3143 | 3316 | 2971 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | |
| Current Port. of LT Debt/Capital Leases | 172 | 208 | 1343 | 152 | 151 |
| Other Current Liabilities, Total | 3284 | 3328 | 2171 | 2110 | 2131 |
| Total Liabilities | 20172 | 20288 | 19807 | 19572 | 18876 |
| Total Long Term Debt | 12322 | 12433 | 11833 | 12595 | 12243 |
| Long Term Debt | 12322 | 12433 | 11833 | 12595 | 12243 |
| Deferred Income Tax | 365 | 367 | 421 | 464 | 560 |
| Minority Interest | |||||
| Other Liabilities, Total | 896 | 945 | 896 | 935 | 820 |
| Total Equity | 5805 | 5748 | 5932 | 5765 | 5347 |
| Common Stock | 2.57 | 3 | 3 | 3 | 3 |
| Additional Paid-In Capital | 10991.4 | 10949 | 10906 | 10895 | 10850 |
| Retained Earnings (Accumulated Deficit) | 4223 | 3920 | 3623 | 3334 | 3107 |
| Treasury Stock - Common | -8509 | -8364 | -7869 | -7740 | -7715 |
| Other Equity, Total | -903 | -760 | -731 | -727 | -898 |
| Total Liabilities & Shareholders’ Equity | 25977 | 26036 | 25739 | 25337 | 24223 |
| Total Common Shares Outstanding | 182.5 | 183.1 | 185.5 | 185.7 | 185.8 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 1091 | 971 | 308 | 227 | 284 |
| Cash From Operating Activities | 2260 | 2942 | 1959 | 1417 | 1254 |
| Cash From Operating Activities | 1130 | 1264 | 1287 | 1202 | 1141 |
| Deferred Taxes | -115 | -138 | -176 | -157 | -177 |
| Non-Cash Items | 238 | 165 | 81 | 126 | 112 |
| Cash Taxes Paid | 255 | 222 | 209 | 215 | 211 |
| Cash Interest Paid | 379 | 343 | 399 | 421 | 398 |
| Changes in Working Capital | -84 | 680 | 459 | 19 | -106 |
| Cash From Investing Activities | -2006 | -2103 | -796 | -1190 | -810 |
| Capital Expenditures | -674 | -640 | -616 | -582 | -459 |
| Other Investing Cash Flow Items, Total | -1332 | -1463 | -180 | -608 | -351 |
| Cash From Financing Activities | -329 | -1235 | -217 | -276 | -452 |
| Financing Cash Flow Items | -31 | -840 | -68 | -85 | -77 |
| Issuance (Retirement) of Stock, Net | -1239 | -465 | -491 | -938 | -1390 |
| Issuance (Retirement) of Debt, Net | 941 | 70 | 342 | 747 | 1015 |
| Foreign Exchange Effects | -75 | -52 | 31 | -5 | -60 |
| Net Change in Cash | -150 | -448 | 977 | -54 | -68 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | 289 | 1091 | 864 | 581 | 325 |
| Cash From Operating Activities | 417 | 2260 | 1700 | 837 | 508 |
| Cash From Operating Activities | 253 | 1130 | 773 | 525 | 255 |
| Deferred Taxes | -27 | -115 | -52 | -28 | -10 |
| Non-Cash Items | 77 | 238 | 194 | 116 | 49 |
| Changes in Working Capital | -175 | -84 | -79 | -357 | -111 |
| Cash From Investing Activities | -222 | -2006 | -1529 | -812 | -613 |
| Capital Expenditures | -164 | -674 | -503 | -338 | -177 |
| Other Investing Cash Flow Items, Total | -58 | -1332 | -1026 | -474 | -436 |
| Cash From Financing Activities | 87 | -329 | -136 | 115 | 144 |
| Financing Cash Flow Items | -62 | -31 | -27 | -26 | -12 |
| Issuance (Retirement) of Stock, Net | -187 | -1239 | -1173 | -962 | -470 |
| Issuance (Retirement) of Debt, Net | 336 | 941 | 1064 | 1103 | 626 |
| Foreign Exchange Effects | -4 | -75 | -127 | -78 | -18 |
| Net Change in Cash | 278 | -150 | -92 | 62 | 21 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Iqvia Company profile
About Iqvia Holdings Inc
IQVIA Holdings Inc. is a provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The Company’s segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. Technology & Analytics Solutions provides critical information, technology solutions and real-world insights and services to its life science clients. Research & Development Solutions, which primarily serves biopharmaceutical clients, is engaged in research and development and provides clinical research and clinical trial services. Contract Sales & Medical Solutions provides contract sales to both biopharmaceutical clients and the broader healthcare market.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Iqvia Holdings Inc revenues increased 22% to $13.87B. Net income increased from $279M to $966M. Revenues reflect Research & Development Solutions segment increase of 31% to $7.56B, Technology & Analytics Solutions segment increase of 14% to $5.53B, Contract Sales & Medical Solutions segment increase of 6% to $784M.
Equity composition
Common Stock $0.01 Par, 05/13/, Shares auth. 150M., 129,606,179 issd. Insiders owns approx. 84.77%
| Industry: | Biotechnology & Medical Research (NEC) |
2400 Ellis Road
DURHAM
NORTH CAROLINA 27703
US
Income Statement
- Annual
- Quarterly
News
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com